Dana-Farber Cancer Institute

When you’re diagnosed with cancer, you want a full range of cutting-edge care, groundbreaking research, and second opinions from leading experts. The Christ Hospital Health Network is proud to be the first and only hospital in Ohio to become a Collaborative Member of the Dana-Farber Cancer Institute.

Our specialty-trained and board-certified experts work with a network of world-renowned experts to offer you the latest in cancer care without the burden of leaving home.

About the Collaborative

The Dana-Farber Cancer Institute in Boston is a principal teaching affiliate of Harvard Medical School and consistently ranks as one of the nation's top cancer programs by U.S. News & World Report.

The collaborative institute brings together some of the world's brightest minds in cancer treatment to improve quality and outcomes. Members are selected on a wide range of rigorous standards and a commitment to advancing best practices in safety and care while sharing new discoveries. 

Plus, we share access to robust educational programs and care planning tools to bring the latest in cancer care home to patients in Greater Cincinnati.

Expanded Care for You

We share a passion with the Dana-Farber Cancer Institute for providing the latest in individualized care right here at home. Our membership gives you greater access to customized treatments for your specific type of cancer, provided by local experts at the #1 hospital in Greater Cincinnati. This means expanded care offerings, such as: 

• A collaborative review of your diagnosis and treatment with leading experts from the nation’s top cancer centers 
• Access when appropriate to virtual consultations in select specialties with collaborative members 
• Online, written second opinions for each patient’s unique type of cancer 
• A plan of care discussed by tumor boards attended by a team of renowned experts 
• Expanded treatment options using the latest in clinical research conducted throughout the collaborative 
• Concierge access to Dana-Farber in Boston when promising treatments and clinical trials are not locally available